JP2007537293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007537293A5 JP2007537293A5 JP2007513409A JP2007513409A JP2007537293A5 JP 2007537293 A5 JP2007537293 A5 JP 2007537293A5 JP 2007513409 A JP2007513409 A JP 2007513409A JP 2007513409 A JP2007513409 A JP 2007513409A JP 2007537293 A5 JP2007537293 A5 JP 2007537293A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- disorder
- composition
- disease
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 claims 3
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 claims 3
- 108040008097 MAP kinase activity proteins Proteins 0.000 claims 3
- 102000019149 MAP kinase activity proteins Human genes 0.000 claims 3
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims 3
- 102000001253 Protein Kinase Human genes 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 108060006633 protein kinase Proteins 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000006029 Cardiomegaly Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 241000232901 Nephroma Species 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000025351 nephroma Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 101000933603 Rattus norvegicus Protein BTG1 Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57128304P | 2004-05-14 | 2004-05-14 | |
| US60/571,283 | 2004-05-14 | ||
| PCT/US2005/016801 WO2005113546A1 (en) | 2004-05-14 | 2005-05-13 | Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007537293A JP2007537293A (ja) | 2007-12-20 |
| JP2007537293A5 true JP2007537293A5 (enExample) | 2008-07-03 |
| JP4993604B2 JP4993604B2 (ja) | 2012-08-08 |
Family
ID=35159977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007513409A Expired - Fee Related JP4993604B2 (ja) | 2004-05-14 | 2005-05-13 | ピロリルピリミジンｅｒｋプロテインキナーゼインヒビターのプロドラッグ |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7358258B2 (enExample) |
| EP (1) | EP1753744B1 (enExample) |
| JP (1) | JP4993604B2 (enExample) |
| KR (1) | KR20070012555A (enExample) |
| CN (1) | CN1976925A (enExample) |
| AT (1) | ATE435858T1 (enExample) |
| AU (1) | AU2005245877B2 (enExample) |
| BR (1) | BRPI0511124A (enExample) |
| CA (1) | CA2566444A1 (enExample) |
| DE (1) | DE602005015319D1 (enExample) |
| IL (1) | IL179206A0 (enExample) |
| MX (1) | MXPA06013208A (enExample) |
| NO (1) | NO20065762L (enExample) |
| NZ (1) | NZ551583A (enExample) |
| RU (1) | RU2006144448A (enExample) |
| UA (1) | UA84929C2 (enExample) |
| WO (1) | WO2005113546A1 (enExample) |
| ZA (1) | ZA200610163B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| US8119667B2 (en) * | 2005-12-29 | 2012-02-21 | Schering-Plough Animal Health Corporation | Carbonates of fenicol antibiotics |
| MX2008010635A (es) | 2006-02-16 | 2008-10-28 | Schering Corp | Derivados de pirrolidina como inhibidores de cinasa regulada por señales extracelulares. |
| WO2009105500A1 (en) | 2008-02-21 | 2009-08-27 | Schering Corporation | Compounds that are erk inhibitors |
| JP2013147428A (ja) * | 2010-04-27 | 2013-08-01 | Dainippon Sumitomo Pharma Co Ltd | 新規２−ヘテロアリール単環ピリミジン誘導体 |
| CN103617111A (zh) * | 2011-04-01 | 2014-03-05 | 北京奇虎科技有限公司 | 一种计算机功耗计算方法及装置 |
| IN2014KN02601A (enExample) | 2012-04-24 | 2015-05-08 | Vertex Pharma | |
| SMT201900107T1 (it) | 2013-03-12 | 2019-02-28 | Vertex Pharma | Inibitori della dna-pk |
| PL3424920T3 (pl) | 2013-10-17 | 2020-11-16 | Vertex Pharmaceuticals Incorporated | Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK |
| US20160264536A1 (en) | 2013-10-23 | 2016-09-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2016192063A1 (en) * | 2015-06-03 | 2016-12-08 | Changzhou Jiekai Pharmatech Co. Ltd | Heterocyclic compounds as erk inhibitors |
| DK3307727T3 (da) * | 2015-06-15 | 2024-01-08 | Asana Biosciences Llc | Heterocykliske inhibitorer af erk1 og erk2 og deres anvendelse i behandlingen af kræft |
| MX394860B (es) | 2016-09-27 | 2025-03-24 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776954A (en) * | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
| AP2003002825A0 (en) * | 2000-12-21 | 2003-09-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| EP1506189A1 (en) * | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| JP4570955B2 (ja) | 2002-07-09 | 2010-10-27 | バーテクス ファーマスーティカルズ インコーポレイテッド | プロテインキナーゼ阻害活性を持つイミダゾール類 |
-
2005
- 2005-05-13 AU AU2005245877A patent/AU2005245877B2/en not_active Expired - Fee Related
- 2005-05-13 US US11/129,114 patent/US7358258B2/en not_active Expired - Fee Related
- 2005-05-13 BR BRPI0511124-2A patent/BRPI0511124A/pt not_active IP Right Cessation
- 2005-05-13 NZ NZ551583A patent/NZ551583A/en unknown
- 2005-05-13 MX MXPA06013208A patent/MXPA06013208A/es not_active Application Discontinuation
- 2005-05-13 CN CNA2005800214194A patent/CN1976925A/zh active Pending
- 2005-05-13 EP EP05756023A patent/EP1753744B1/en not_active Expired - Lifetime
- 2005-05-13 CA CA002566444A patent/CA2566444A1/en not_active Abandoned
- 2005-05-13 KR KR1020067026319A patent/KR20070012555A/ko not_active Withdrawn
- 2005-05-13 RU RU2006144448/04A patent/RU2006144448A/ru not_active Application Discontinuation
- 2005-05-13 AT AT05756023T patent/ATE435858T1/de not_active IP Right Cessation
- 2005-05-13 JP JP2007513409A patent/JP4993604B2/ja not_active Expired - Fee Related
- 2005-05-13 UA UAA200613207A patent/UA84929C2/ru unknown
- 2005-05-13 WO PCT/US2005/016801 patent/WO2005113546A1/en not_active Ceased
- 2005-05-13 DE DE602005015319T patent/DE602005015319D1/de not_active Expired - Lifetime
- 2005-05-13 ZA ZA200610163A patent/ZA200610163B/en unknown
-
2006
- 2006-11-13 IL IL179206A patent/IL179206A0/en unknown
- 2006-12-13 NO NO20065762A patent/NO20065762L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007537293A5 (enExample) | ||
| CN1177833C (zh) | 取代的间二氮杂萘衍生物 | |
| EP2598480B1 (en) | Cyclopropylamine derivatives useful as lsd1 inhibitors | |
| JP6043935B2 (ja) | ピペラジノトリアゾール化合物及びその製造方法と製薬用途 | |
| Ahsan et al. | Synthesis, antiproliferative activity, and molecular docking studies of curcumin analogues bearing pyrazole ring | |
| MX2007004882A (es) | Derivados de xantina con actividad de receptor de hm74a. | |
| RU2009137390A (ru) | Аминопиримидины, пригодные в качестве ингибиторов протеинкиназ | |
| BR0310106A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica | |
| JP2009537498A5 (enExample) | ||
| EP1688412A3 (en) | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | |
| ATE313534T1 (de) | Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden | |
| JP6855466B2 (ja) | Ｌｓｄ１阻害剤に関連するバイオマーカーおよびそれらの使用 | |
| JP2012509279A5 (enExample) | ||
| MX2008000019A (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o ciclico, y su uso como productos farmaceuticos. | |
| DE502005010170D1 (de) | Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel | |
| DE602004005502D1 (de) | Comt-inhibitoren | |
| JP2010540649A5 (enExample) | ||
| MX2010006719A (es) | Compuestos y metodos para el tratamiento de enfermedad vascular. | |
| RU2010132912A (ru) | Гидроксилированный пиримидил циклопентан в качестве ингибитора протеинкиназы (акт) | |
| UA88634C2 (en) | Quaternized quinuclidine esters | |
| Fan et al. | Design, synthesis and evaluation of 2-amino-imidazol-4-one derivatives as potent β-site amyloid precursor protein cleaving enzyme 1 (BACE-1) inhibitors | |
| WO2002066468A3 (en) | Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands | |
| JP2008519056A5 (enExample) | ||
| JP2008543813A5 (enExample) | ||
| WO2003030922A3 (en) | Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis |